A Clinical Study Evaluating the Pharmacokinetic Effects of SHR4640 on Repaglinide and Midazolam in Healthy Subjects and the Impact of SHR4640 on QT Interval
Latest Information Update: 09 Mar 2024
At a glance
- Drugs Ruzinurad (Primary) ; Midazolam; Repaglinide
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 05 Mar 2024 Status changed from recruiting to completed.
- 05 Feb 2024 Status changed from not yet recruiting to recruiting.
- 11 Jan 2024 New trial record